Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
861-880 of 1,738 trials

Myelodysplastic Syndrome: Targeted Treatment After Stem Cell Transplant

We are studying a new approach to prevent relapse and improve survival in patients with myelodysplastic syndrome after stem cell transplantation. The trial focuses on those with minimal residual disease to see if personalized treatment can help.

Myelodysplastic Syndrome>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Solid Tumors: 68Ga-FAPI-46 PET-CT Imaging Study

We are testing a new imaging method to see if it can better identify issues in solid tumors when previous scans were unclear. This study aims to improve risk assessment and safety for patients with various tumor types.

Solid Tumor>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Prostate Cancer: Radium-223 and Docetaxel Study

We are exploring whether using Radium-223 followed by Docetaxel helps men with bone-only metastatic prostate cancer feel better and live longer. This study will compare the effects of these treatments on quality of life and survival.

Metastatic Castration-Resistant Prostate CancerSymptomatic Bone-Only Metastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

NVDX3 Implant: Long-Term Safety Study

We are examining the long-term safety of the NVDX3 osteogenic implant made from human tissue. This study aims to ensure it is safe for patients who may need this type of treatment.

Low Grade Degenerative Lumbar SpondylolisthesisDistal Radius Fracture>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOrthopedics and Traumatology

Anorexia Nervosa: Donepezil Treatment Study

We are investigating whether donepezil can help improve symptoms and support weight gain in adult women with anorexia nervosa. This study compares its effects to a placebo to understand its potential benefits.

Anorexia Nervosa3-6 monthsEfficacy phase (II)Standard MedicinesPsychiatry

Long-term Safety of Genetically Modified T Cell Therapy

We are following up with patients who received genetically modified T cells to assess their long-term safety and survival. This study aims to understand how well the treatment works and any potential risks involved.

Acute Lymphoblastic LeukemiaSystemic Lupus ErythematosusNon-Hodgkin's Lymphoma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncologyRheumatology

Myelofibrosis: Testing RVU120

We are studying the investigational drug RVU120 for patients with myelofibrosis to see if it helps reduce cancer symptoms and improve treatment outcomes. This trial will also assess its safety and effectiveness when used alone or with another medication.

MyelofibrosisEfficacy phase (II)No PlaceboInvestigational MedicinesHematology

Dexamethasone for Congenital Adrenal Hyperplasia in Pregnancy

We are studying whether a lower dose of dexamethasone can effectively prevent prenatal complications in female babies with congenital adrenal hyperplasia. We will also monitor the health of mothers and their children during and after pregnancy.

Congenital Adrenal HyperplasiaEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyGynecology and Obstetrics

Lung Fibrosis: ENV-101 Treatment Study

We are testing a new medication, ENV-101, for people with lung fibrosis to see if it improves lung function and overall health. The study will also look at the safety of this treatment.

Idiopathic Pulmonary Fibrosis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Felzartamab for Late Antibody-Mediated Rejection

We are studying whether Felzartamab can help patients experiencing late antibody-mediated rejection after a transplant. This research aims to improve treatment options for these patients.

Late Antibody Mediated Renal Transplant Rejection>2 yearsEfficacy phase (II)Internal MedicineNephrology

Kidney Disease: Frexalimab, Brivekimig, and Rilzabrutinib Study

We are testing three new medications for people aged 16 to 75 with primary focal segmental glomerulosclerosis or minimal change disease. The goal is to see if they can reduce protein in urine and improve kidney function compared to a placebo.

Focal Segmental Glomerulosclerosis (FSGS)Minimal Change Disease (MCD)Immune System Diseases1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineNephrology

Ovarian Cancer: Olaparib and Durvalumab Study

We are exploring whether Olaparib alone or with Durvalumab can be safely given to patients with high-grade ovarian cancer before surgery. This study may help us learn more about treatment effectiveness and safety.

Ovarian Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Liver Fibrosis Assessment: 68Ga-FAPI Imaging Study

We are studying a new imaging technique to evaluate liver fibrosis in patients with suspected nonalcoholic steatohepatitis. This may help improve the accuracy of liver damage assessments compared to standard methods.

Non-Alcoholic Steatohepatitis (NASH)>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyHepatologyInternal Medicine

Advanced NSCLC: NVL-520 Treatment Study

We are testing a new medication, NVL-520, for patients with advanced ROS1-positive solid tumors, including non-small cell lung cancer. The study aims to find the best dose and evaluate its effectiveness and safety.

Advanced ROS1-positive Lung CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Multiple Myeloma: Belantamab Mafodotin and Venetoclax Combination

We are testing a new combination treatment for patients with relapsed and refractory t(11;14) multiple myeloma. The goal is to see if this approach improves outcomes compared to current therapies.

Relapsed/Refractory Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)HematologyOncology

Cardiogenic Shock: Beta Receptor Modulation Trial

We are testing a new approach to manage heart function in patients with cardiogenic shock on V-A ECMO. This study compares reducing beta receptor stimulation to the usual treatment to see which is safer and more effective.

Cardiogenic Shock>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Crohn's Disease: Stem Cell Treatment Study

We are exploring the use of fat-derived stem cells to treat fistulas in people with Crohn's disease. The goal is to find the best dose that may help improve healing.

Crohn’s Fistula1-2 yearsSafety phase (I)Efficacy phase (II)GastroenterologyInternal Medicine

Duchenne Muscular Dystrophy: Givinostat Study for Young Boys

We are studying the safety and effects of givinostat in boys aged 2 to under 6 years with Duchenne Muscular Dystrophy. This trial aims to understand how the drug works in their bodies and its impact on muscle function.

Duchenne Muscular DystrophyEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOrthopedics and Traumatology

Type 2 Diabetes: Dapansutrile Study

We are testing a new oral medication for people with type 2 diabetes to see if it helps lower blood sugar levels better than a placebo. The study also looks at its safety and effects on insulin function.

Type 2 Diabetes6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDiabetologyEndocrinology

Unresectable Malignant Mesothelioma: Tremelimumab Study

We are comparing a new treatment called tremelimumab to a placebo for patients with unresectable malignant mesothelioma. The goal is to see if it improves survival and overall health outcomes.

Malignant Mesothelioma>2 yearsEfficacy phase (II)Investigational MedicinesOncology